PDB11 Real-world cost-effectiveness of SGLT-2 inhibitors versus DPP-4 inhibitors for type 2 diabetes: A modeling study
Jun 1, 2021, 00:00 AM
10.1016/j.jval.2021.04.409
https://www.valueinhealthjournal.com/article/S1098-3015(21)00626-4/fulltext
Section Title :
Section Order :
10971
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00626-4&doi=10.1016/j.jval.2021.04.409